Find representative publications from CIPREVO below. Additionnal ones are available on Google scholar.
Babae N, Bourajjaj M, Liu Y, Van Beijnum JR, Cerisoli F, Scaria PV, Verheul M, Van Berkel MP, Pieters EH, Van Haastert RJ, Yousefi A, Mastrobattista E, Storm G, Berezikov E, Cuppen E, Woodle M, Schaapveld RQ, Prevost GP, Griffioen AW, Van Noort PI, Schiffelers RM.
Oncotarget. 2014 Aug 30;5(16):6687-700.
Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C.
Clin Cancer Res. 2012 Oct 1;18(19):5314-28. doi: 10.1158/1078-0432.CCR-12-0372. Epub 2012 Jul 23.
Ayoub MA, Damian M, Gespach C, Ferrandis E, Lavergne O, De Wever O, Banères JL, Pin JP, Prévost GP.
J Biol Chem. 2009 Oct 16;284(42):29136-45. doi: 10.1074/jbc.M109.042333. Epub 2009 Jul 31.
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers
Michèle Sabbah, Shahin Emami, Gérard Redeuilh, Sylvia Julien, Grégoire Prévost, Amazia Zimbera, Radia Ouelaaa, Marc Bracke, Olivier De Weverab, Christian Gespachab
Drug Resistance Updates Volume 11, Issues 4–5, August–October 2008, Pages 123-151
Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex
Prévost GP, Lonchampt MO, Holbeck S, Attoub S, Zaharevitz D, Alley M, Wright J, Brezak MC, Coulomb H, Savola A, Huchet M, Chaumeron S, Nguyen QD, Forgez P, Bruyneel E, Bracke M, Ferrandis E, Roubert P, Demarquay D, Gespach C, Kasprzyk PG.
Cancer Res. 2006 Sep 15;66(18):9227-34.